Legal entity
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention ADMA Biologics, Inc., the most common co-covered peer. Their average consequence score of 7 runs above the beat's 6.5 for that window.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention ADMA Biologics, Inc., the most common co-covered peer. Their average consequence score of 7 runs above the beat's 6.5 for that window. Source depth averages 4 original sources per story, versus 4.6 across the same-window beat baseline. We currently track 1 Legal story that mention Omnipod 5, all published on July 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 33 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Omnipod 5. Shared-story counts are live from our verified record — not editorial picks.
BFA Law launches coordinated class actions against Microsoft, ADMA, Insulet, and Embecta over product-related misrepresentations, with lead plaintiff deadlines in August.
Source: stockhouse.com · stockhouse.com
Omnipod 5 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
